Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Devous

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
EJNMMI Research|June 17, 2020
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological studyMichael J Pontecorvo, C Dirk Keene, Thomas G Beach, et al.
Annals of Neurology|October 6, 2017
<sup>18</sup> F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter studyDaniel R Schonhaut, Corey T McMillan, Salvatore Spina, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 20, 2020
The impact of demographic, clinical, genetic, and imaging variables on tau PET statusRik Ossenkoppele, Antoine Leuzy, Hanna Cho, et al.
JAMA Neurology|June 28, 2021
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance ImagingRik Ossenkoppele, Ruben Smith, Niklas Mattsson-Carlgren, et al.
JAMA Neurology|April 28, 2020
Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic ChangesAdam S Fleisher, Michael J Pontecorvo, Michael D Devous, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
EJNMMI Research|June 17, 2020
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological studyMichael J Pontecorvo, C Dirk Keene, Thomas G Beach, et al.
Annals of Neurology|October 6, 2017
<sup>18</sup> F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter studyDaniel R Schonhaut, Corey T McMillan, Salvatore Spina, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 20, 2020
The impact of demographic, clinical, genetic, and imaging variables on tau PET statusRik Ossenkoppele, Antoine Leuzy, Hanna Cho, et al.
JAMA Neurology|June 28, 2021
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance ImagingRik Ossenkoppele, Ruben Smith, Niklas Mattsson-Carlgren, et al.
JAMA Neurology|April 28, 2020
Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic ChangesAdam S Fleisher, Michael J Pontecorvo, Michael D Devous, et al.
Pageof 8